**Background of SNCG Antibody**
γ-Synuclein (SNCG), a member of the synuclein family, is a small, acidic protein primarily expressed in the nervous system. Unlike α-synuclein (linked to Parkinson’s disease), SNCG is notably upregulated in various cancers, including breast, ovarian, and liver cancers, where it promotes tumor progression, metastasis, and chemoresistance. Its oncogenic role involves interactions with cell cycle regulators, signaling pathways (e.g., PI3K/AKT), and cytoskeletal proteins, enhancing proliferation and invasiveness.
SNCG antibodies are critical tools for detecting and quantifying SNCG expression in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study SNCG’s tissue distribution, overexpression in malignancies, and subcellular localization. These antibodies aid in exploring SNCG’s role as a potential biomarker for cancer prognosis or therapeutic targeting.
Most SNCG antibodies are raised against specific epitopes, often in rabbits or mice, and validated for specificity to avoid cross-reactivity with α- or β-synuclein. Commercial antibodies may vary in clonality (monoclonal/polyclonal), conjugation (e.g., HRP, fluorescent tags), and applications. Researchers must verify antibody performance in their experimental systems, as SNCG’s low molecular weight (~13 kDa) and homology to other synucleins pose challenges in assay design.